期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CYP2C19基因型检测在冠心病患者新型抗血小板治疗方案选择中的价值 被引量：5

下载PDF
导出
摘要 当前,冠状动脉粥样硬化性心脏病仍是造成国人致死和致残的主要病因之一。抗血小板治疗是冠心病治疗的重要组成部分,氯吡格雷与阿司匹林的双联用药已成为急性冠状动脉综合征（acute coronary syndrome,ACS）/经皮冠状动脉介入治疗（percutaneous coronary intervention,PCI）患者的标准治疗方案,但仍有大量血栓事件发生。
作者 徐玲 赵威 崔鸣 高炜
机构地区 北京大学第三医院心内科卫生部心血管分子生物学与调节肽重点实验室分子心血管学教育部重点实验室心血管受体研究北京市重点实验室
出处 《中国介入心脏病学杂志》 2016年第5期277-279,共3页 Chinese Journal of Interventional Cardiology
基金 中国心血管医师研究基金(2013年)
关键词 CYP2C19基因多态性 新型抗血小板治疗 冠心病 经皮冠状动脉介入治疗
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献23

  • 1Norgard NB,Di Nicolantonio JJ.P2Y12antagonists in non-STsegment elevation acute coronary syndromes:latest evidence and optimal use.Ther Adv Chronic Dis,2015,6(4):204-218.
  • 2Mao L,Jian C,Changzhi L,et al.Cytochrome CYP2C19polymorphism and risk of adverse clinical events in clopidogreltreated patients:a meta-analysis based on 23,035 subjects.Arch Cardiovasc Dis,2013,106(10):517-527.
  • 3Scott SA,Sangkuhl K,Shuldiner AR,et al.Pharm GKB summary:very important pharmacogene information for cytochrome P450,family 2,subfamily C,polypeptide 19.Pharmacogenet Genomics,2012,22(2):159-165.
  • 4Scott SA,Sangkuhl K,Stein CM,et al.Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy:2013 update.Clin Pharmacol Ther,2013,94(3):317-323.
  • 5Hulot JS,Bura A,Villard E,et al.Cytochrome P450 2C19 lossof-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.Blood,2006,108(7):2244-2247.
  • 6Sabatine MS,Mega JL.Pharmacogenomics of antiplatelet drugs.Hematology Am Soc Hematol Educ Program,2014,1:343-347.
  • 7Jang JS,Cho KI,Jin HY,et al.Meta-analysis of cytochrome P4502C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.Am J Cardiol,2012,110(4):502-508.
  • 8Zabalza M,Subirana I,Sala J,et al.Meta-analyses of theassociation between cytochrome CYP2C19 loss-and gain-offunction polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.Heart,2012,98(2):100-108.
  • 9Amsterdam EA,Wenger NK,Brindis RG,et al.2014 AHA/ACC guideline for the management of patients with non-STelevation acute coronary syndromes:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Circulation,2014,130(25):2354-2394.
  • 10Roffi M,Patrono C,Collet JP,et al.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.Kardiol Pol,2015,73(12):1207-1294.

二级参考文献29

  • 1Price MJ,Murray SS,Angiolillo DJ,et al.Influence of genetic polymorphisms on the effect of high-and standard-dose clopidogrel after percutaneous coronary intervention:the GIFT(Genotype Information and Functional Testing)study.Am Coll Cardiol,2012,59:1928-1937.
  • 2Wu H,Qian J,Sun A,et al.Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.Circ J,2012,76:2773-2778.
  • 3Zhang L,Chen Y,Jin Y,et al.Genetic determinants of high ontreatment platelet reactivity in clopidogrel treated Chinese patients.Thromb Res,2013,132:81-87.
  • 4ParéG,Mehta SR,Yusuf S,et al.Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.N Engl J Med,2010,363:1704-1714.
  • 5Park J.Backtracking on CYP2C19 genotyping in clopidogrel therapy?Biomark Med,2010,4:791.
  • 6Jang JS,Cho KI,Jin HY,et al.Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.Am J Cardiol,2012,110:502-508.
  • 7Chen DY,Wang CY,Wen MS,et al.Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwan Residents population.PLo S One,2012,7:e39178.
  • 8Tresukosol D,Suktitipat B,Hunnangkul S,et al.Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.PLo S One,2014,9:e110188.
  • 9Delaney JT,Ramirez AH,Bowton E,et al.Predicting clopidogrel response using DNA samples linked to an electronic health record.Clin Pharmacol Ther,2012,91:170-171.
  • 10Luo M,Li J,Xu X,et al.ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients:a meta-analysis.Thromb Res,2012,129:754-759.

共引文献9

同被引文献38

引证文献5

二级引证文献10

中国介入心脏病学杂志
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部